bullish

Kalbe Farma

Kalbe Farma (KLBF.IJ) - Resilient Growth Outlook at Reasonable Valuation

165 Views14 May 2024 19:55
Broker
Unbranded Generic and distribution to drive FY24F top line, while CH and Nutrition revenue normalized We raised FY24-25F NP by 4.5-2.9%, driven by the absence of covid inventory provision forex gain
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 10-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
BRI Danareksa Research
External broker reports(aggregated public sources)
BRI Danareksa Research
IndonesiaEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • Kalbe Farma (KLBF.IJ) - Resilient Growth Outlook at Reasonable Valuation
    14 May 2024
x